Sign In
Buy COLL
$31.06
+0.580 (+1.90%)
At Close: Jun 03, 2026
Collegium Pharmaceutical (COLL) Soars 10.6%: Is Further Upside Left in the Stock?
07:56am, Wednesday, 31'st Jul 2024
Collegium Pharmaceutical (COLL) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further stre
Collegium to Acquire Ironshore Therapeutics, Expanding into Neurology
06:00am, Monday, 29'th Jul 2024
– Adds Commercial Product Jornay PM ® , Establishing Collegium's Presence in Neurology (ADHD) –
7 Biotech Stocks to Buy on the Dip: June 2024
12:56pm, Monday, 24'th Jun 2024
Fundamentally, the biotechnology sphere enjoys a powerful catalyst: wealth without health means nothing. Yes, it's important to save money and invest for the future.
Collegium to Participate in Jefferies Global Healthcare Conference
08:00am, Wednesday, 29'th May 2024
STOUGHTON, Mass., May 29, 2024 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a leading, diversified specialty pharmaceutical company committed to improving the lives of people li
Amalgamated Bank Has $427,000 Holdings in Collegium Pharmaceutical, Inc. (NASDAQ:COLL)
05:04am, Monday, 20'th May 2024
Amalgamated Bank decreased its position in Collegium Pharmaceutical, Inc. (NASDAQ:COLL – Free Report) by 13.2% during the 4th quarter, according to its most recent Form 13F filing with the Secur
Collegium Announces $35 Million Accelerated Share Repurchase Program
08:00am, Monday, 13'th May 2024
STOUGHTON, Mass., May 13, 2024 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a leading, diversified specialty pharmaceutical company committed to improving the lives of people liv
Collegium Pharmaceutical, Inc. (COLL) Q1 2024 Earnings Call Transcript
07:32pm, Thursday, 09'th May 2024
Collegium Pharmaceutical, Inc. (NASDAQ:COLL ) Q1 2024 Results Conference Call May 9, 2024 4:30 PM ET Company Participants Christopher James - Vice President of Investor Relations Joe Ciaffoni - Chief
Collegium Pharmaceutical (COLL) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates
07:01pm, Thursday, 09'th May 2024
The headline numbers for Collegium Pharmaceutical (COLL) give insight into how the company performed in the quarter ended March 2024, but it may be worthwhile to compare some of its key metrics to Wal
Collegium Pharmaceutical (COLL) Q1 Earnings and Revenues Lag Estimates
06:40pm, Thursday, 09'th May 2024
Collegium Pharmaceutical (COLL) came out with quarterly earnings of $1.45 per share, missing the Zacks Consensus Estimate of $1.49 per share. This compares to earnings of $1.32 per share a year ago.
Collegium Reports First Quarter 2024 Financial Results
04:02pm, Thursday, 09'th May 2024
– Generated Q1'24 Net Revenue of $144.9 Million – – Delivered Q1'24 Record Belbuca ® Revenue of $50.7 Million; Total Prescriptions Up 4.2% Year-over-Year – – Achieved Q1'24 GAAP Net Income
Unlocking Q1 Potential of Collegium Pharmaceutical (COLL): Exploring Wall Street Estimates for Key Metrics
10:20am, Tuesday, 07'th May 2024
Besides Wall Street's top -and-bottom-line estimates for Collegium Pharmaceutical (COLL), review projections for some of its key metrics to gain a deeper understanding of how the company might have fa
Collegium Pharmaceutical (COLL) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
11:06am, Thursday, 02'nd May 2024
Collegium Pharmaceutical (COLL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Collegium (COLL) to Report Q1 Earnings: Here's What to Expect
10:46am, Monday, 29'th Apr 2024
Collegium's (COLL) top line is likely to have been fueled by growth in the sales of pain drugs, Belbuca and Xtampza ER, in the first quarter of 2024.
Collegium to Report First Quarter 2024 Financial Results on May 9, 2024
08:00am, Thursday, 25'th Apr 2024
STOUGHTON, Mass., April 25, 2024 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a leading, diversified specialty pharmaceutical company committed to improving the lives of people
Collegium Pharmaceutical, Inc. Announces Redemption of Outstanding 2.625% Convertible Senior Notes Due 2026
08:00am, Thursday, 11'th Apr 2024
STOUGHTON, Mass., April 11, 2024 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL) (the “Company”), a leading, diversified specialty pharmaceutical company committed to improving t
